Angiogenesis is the formation of new blood vessels from existing ones and an underlying cause of numerous human diseases, including cancer and inflammation. A large body of evidence indicates that angiogenic inhibitors have therapeutic potential in the treatment of vascular diseases. However, detrimental side effects and low efficacy hinder their use in clinical practice. Members of the corticotropin-releasing hormone (CRH) family, which comprises CRH, urocortin I-III, and CRH receptors (CRHR) 1 and 2, are broadly expressed in the brain and peripheral tissues, including the intestine and cardiovascular system. The CRH family regulates stress-related responses through the hypothalamic-pituitary-adrenal axis. Therapeutic agents that target CRH family members offer a new approach to the treatment of various gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and colorectal cancer. Since the discovery that CRHR 2 has anti-angiogenic activity during postnatal development in mice, studies have focused on the role of the CRH system in the modulation of blood vessel formation and cardiovascular function. This review will outline the basic biological functions of the CRH family members and the implications for the development of novel anti-angiogenic therapies.

Citations

Citations to this article as recorded by  

• Nervous system in colorectal cancer
  Chunjie Xu, Chunhui Jiang, Yuan Tian, Ye Liu, Hao Zhang, Zeyu Xiang, Hanbing Xue, Lei Gu, Qing Xu
  Cancer Letters.2025; 611: 217431.     CrossRef
• Vascular anomalies in Koolen‐de Vries syndrome: Expanding the spectrum of cutaneous findings
  María Trinidad Hasbun Zegpi, Daniela Alfaro‐Sepúlveda, Luisa Schonhaut Berman, Cecilia Mellado Sagredo
  JEADV Clinical Practice.2024; 3(2): 726.     CrossRef
• The peripheral corticotropin releasing factor family's role in vasculitis
  Chao Zhu, Shengnan Li
  Vascular Pharmacology.2024; 154: 107275.     CrossRef
• Disentangling the common genetic architecture and causality of rheumatoid arthritis and systemic lupus erythematosus with COVID‐19 outcomes: Genome‐wide cross trait analysis and bidirectional Mendelian randomization study
  Minhao Yao, Xin Huang, Yunshan Guo, Jie V. Zhao, Zhonghua Liu
  Journal of Medical Virology.2023;[Epub]     CrossRef
• Steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapies
  Matthew Goldman, Brandon Lucke-Wold, Meleine Martinez-Sosa, Jason Katz, Yusuf Mehkri, Jeff Valisno, Stephan Quintin
  Exploration of Targeted Anti-tumor Therapy.2022; : 659.     CrossRef
• Corticotropin-Releasing Hormone Receptor Alters the Tumor Development and Growth in Apcmin/+ Mice and in a Chemically-Induced Model of Colon Cancer
  Yunna Lee, Elise L. Ma, Marisa Patel, Gayoung Kim, Cody Howe, Charalabos Pothoulakis, Yong Sung Kim, Eunok Im, Sang Hoon Rhee
  International Journal of Molecular Sciences.2021; 22(3): 1043.     CrossRef
• Cancer-Specific Loss of Urocortin 3 in Human Renal Cancer
  Pouriya Faraj Tabrizi, Anahit Mohebbi Tafrechi, Inga Peters, Faranaz Atschekzei, Markus Antonius Kuczyk, Jürgen Serth, Hossein Tezval
  Advances in Therapy.2020; 37(1): 288.     CrossRef
• Methylation Status of Transcriptional Modulatory Genes Associated with Colorectal Cancer in Northeast China
  Han-Lu Gao, Xuan Wang, Hong-Ru Sun, Jun-De Zhou, Shang-Qun Lin, Yu-Hang Xing, Lin Zhu, Hai-Bo Zhou, Ya-Shuang Zhao, Qiang Chi, Yu-Peng Liu
  Gut and Liver.2018; 12(2): 173.     CrossRef
• CRHR2/Ucn2 signaling is a novel regulator of miR‐7/YY1/Fas circuitry contributing to reversal of colorectal cancer cell resistance to Fas‐mediated apoptosis
  Charalabos Pothoulakis, Monica Torre‐Rojas, Marco A. Duran‐Padilla, Jonathan Gevorkian, Odysseas Zoras, Emmanuel Chrysos, George Chalkiadakis, Stavroula Baritaki
  International Journal of Cancer.2018; 142(2): 334.     CrossRef
• Angiogenesis in Inflammatory Bowel Disease
  Canan Alkim, Huseyin Alkim, Ali Riza Koksal, Salih Boga, Ilker Sen
  International Journal of Inflammation.2015; 2015: 1.     CrossRef
• P7, a novel antagonist of corticotropin releasing factor receptor type 1 (CRFR1) screened from phage display library
  Jinmei Yu, Rengong Zhuo, Peng Peng, Xiaoyan Liu, Haitao Yan, Shuzhuo Zhang, Jianquan Zheng, Xiaoli Wei, Xiaoyun Ma
  Biochemical and Biophysical Research Communications.2015; 463(3): 200.     CrossRef
• Corticotropin-releasing factor mediates bone cancer induced pain through neuronal activation in rat spinal cord
  Hou-bao Fan, Ting Zhang, Kai Sun, Su-pei Song, Shou-bin Cao, Hai-long Zhang, Wen Shen
  Tumor Biology.2015; 36(12): 9559.     CrossRef
• Corticotropin Releasing Hormone and Urocortin 3 Stimulate Vascular Endothelial Growth Factor Expression through the cAMP/CREB Pathway
  Sang Hoon Rhee, Elise L. Ma, Yunna Lee, Yvette Taché, Charalabos Pothoulakis, Eunok Im
  Journal of Biological Chemistry.2015; 290(43): 26194.     CrossRef